RA
RADX.US Radiopharm Theranostics Limited American Depositary Shares
- Market cap
- USD 10.5M
- P/E
- -
- P/B
- 0.72x
- ROE
- -218.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RADX.US undervalued?
Graham numberThe Graham number of Radiopharm Theranostics Limited American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Radiopharm Theranostics Limited American Depositary Shares fundamental analysis
No fundamental analysis for Radiopharm Theranostics Limited American Depositary Shares yet.
Radiopharm Theranostics Limited American Depositary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; …
Full company profileRadiopharm Theranostics Limited American Depositary Shares financial statements
Radiopharm Theranostics Limited American Depositary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 8.83K | 292K | 299K | 3.63M | 2.71M |
| Gross Profit | 8.83K | 292K | 299K | 39.3K | -2.10M |
| Operating Income | -19.9M | -34.5M | -36.6M | -38.2M | -66.8M |
| EBITDA | -18.0M | -31.2M | -44.2M | -35.5M | -64.1M |
| Net Income | -30.3M | -34.6M | -47.9M | -38.3M | -53.9M |
| EPS | -30 | -34 | -37 | -5.53 | -4.57 |
| Balance Sheet | |||||
| Total Assets | 83.4M | 74.9M | 72.0M | 86.5M | 60.1M |
| Total Liabilities | 20.4M | 29.4M | 44.7M | 43.6M | 37.8M |
| Shareholders' Equity | 63.0M | 44.4M | 28.1M | 44.8M | 24.7M |
| Cash & Short-term Investments | 27.0M | 11.7M | 18.6M | 29.1M | 4.14M |
| Cash Flow | |||||
| Operating Cash Flow | -9.92M | -23.2M | -23.0M | -36.6M | -51.6M |
| Capital Expenditure | 28.3M | 1.53M | 0.00 | 0.00 | 51.6M |
| Free Cash Flow | -38.3M | -24.7M | -23.0M | -36.6M | -52.8M |
| Ratios | |||||
| ROE | -48.2% | -78.0% | -170.5% | -85.6% | -218.5% |
| ROA | -36.4% | -46.2% | -66.6% | -44.3% | -89.7% |
| Net Profit Margin | -343,550.9% | -11,838.6% | -16,024.3% | -1,055.3% | -1,992.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Radiopharm Theranostics Limited American Depositary Shares dividends
Radiopharm Theranostics Limited American Depositary Shares has not paid dividends in the last 6 fiscal years.
Who owns Radiopharm Theranostics Limited American Depositary Shares
- Insiders 0.00%
- Institutions 9.61%
- Public & others 90.39%
- Shares outstanding 15.7M
- Free float 12.0M
Top institutions holding RADX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Stonepine Capital Management Llc | 51.0M | 0.00% | 0.00% | Jun 2026 |
| HSBC Holdings PLC | 62.2K | 0.40% | +1.33% | Jun 2026 |
| VGI Partners Ltd | 40.1K | 0.26% | 0.00% | Jun 2026 |
| PNC Financial Services Group Inc | 20.0K | 0.13% | +25.00% | Jun 2026 |
| UBS Group AG | 1.51K | 0.01% | -49.77% | Jun 2026 |
| Integrated Wealth Concepts LLC | 1.31K | 0.01% | 0.00% | Jun 2026 |
| Rhumbline Advisers | 195.00 | 0.00% | 0.00% | Sep 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Radiopharm Theranostics Limited American Depositary Shares company profile
- Company name
- Radiopharm Theranostics Limited American Depositary Shares
- Ticker
- RADX.US
- Exchange
- USA Stocks
- Listed since
- Dec 5, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- June
- Address
- 62 Lygon Street, Carlton, VIC, Australia, 3053
- Phone
- 61 3 9824 5254
- Website
- radiopharmtheranostics.com
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Radiopharm Theranostics Limited American Depositary Shares management
7- Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDFounder & Executive Chairman · born 1956
- Mr. Riccardo CanevariMD, CEO & Director
- Dr. Dimitris Voliotis M.D.Chief Medical Officer · born 1963
- Mr. Aaron LauritaChief Financial Officer
- Mr. Hitesh GoelHead of Project Management
- Mr. Nathan Jong C.A.Joint Company Secretary
- Ms. Amritha SushilJoint Company Secretary